Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 63Temozolomide 59Magnetic Resonance Spectroscopy 46Carboplatin 40Cyclophosphamide 39Vincristine 35Specimen Handling 28Etoposide 26Cisplatin 26Radiation 22Chemotherapy, Adjuvant 22Filgrastim 20Bevacizumab 20Doxorubicin 18Peripheral Blood Stem Cell Transplantation 17Biopsy 17Vorinostat 16Surgical Procedures, Operative 14Melphalan 13Immunoglobulin G 13Disulfides 13Radiotherapy, Conformal 12Isotretinoin 12Erlotinib Hydrochloride 12X-Rays 11Nivolumab 11Irinotecan 11Carmustine 11aldesleukin 10Topotecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × guadecitabine × CNS × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡